BioVersys AG (XSWX:BIOV) EBITDA per Share: CHF-3.65 (TTM As of Dec. 2025)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF27.00
View Full Analysis

What is BioVersys AG EBITDA per Share?

BioVersys AG XSWX:BIOV 4 EBITDA per Share is CHF-3.65 as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100. Among 1,136 Biotechnology companies, BioVersys AG ranks worse than 88028.08% on this metric.

BioVersys AG's EBITDA per Share for the six months ended in Dec. 2025 was CHF-1.73. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.65.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for BioVersys AG's EBITDA per Share or its related term are showing as below:

XSWX:BIOV's 3-Year EBITDA Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 14.85
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

BioVersys AG's EBITDA for the six months ended in Dec. 2025 was CHF-10.12 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


BioVersys AG  (XSWX:BIOV) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


BioVersys AG EBITDA per Share Related Terms


BioVersys AG EBITDA per Share Historical Data

* Premium members only.

The historical data trend for BioVersys AG's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG EBITDA per Share Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
EBITDA per Share
-2.94 -3.64

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
EBITDA per Share -1.64 -1.31 -1.92 -1.73
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

BioVersys AG's EBITDA per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA per Share(A: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-20.44/5.615
=-3.64

BioVersys AG's EBITDA per Share for the quarter that ended in Dec. 2025 is calculated as

EBITDA per Share(Q: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-10.118/5.849
=-1.73

EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-3.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of CHF-3.65 mean?
BioVersys AG (XSWX:BIOV) has a EBITDA per Share of CHF-3.65 as of Dec. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on BioVersys AG and its competitors. According to the industry distribution chart, BioVersys AG ranks #999999 out of 1136 companies in the Biotechnology industry.
Is BioVersys AG's EBITDA per Share too high?
BioVersys AG's current EBITDA per Share is CHF-3.65. Based on the distribution chart, BioVersys AG ranks #999999 out of 1136 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's EBITDA per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #999999 out of 1136 companies for EBITDA per Share. This places BioVersys AG in the lower half of its industry. The industry median EBITDA per Share is 14.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Biotechnology company?
The median EBITDA per Share among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on BioVersys AG and its competitors. For the Biotechnology industry, the median EBITDA per Share is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioVersys AG's current EBITDA per Share is CHF-3.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current EBITDA per Share of CHF-3.65. The current EBITDA per Share is CHF-3.65. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current EBITDA per Share is CHF-3.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.00
Price